Glutamate modulators as novel interventions for mood disorders
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Recent evidence suggests that critical molecules in neurotrophic signaling cascades are long-term targets for currently available monoaminergic antidepressants. As chronic and severe mood disorders are characterized by impairments in neuronal resilience, pharmacological strategies that subserve a neuroprotective function might alter disorder pathophysiology and modify disease progression. Several promising approaches involve modulation of the glutamate neurotransmitter system, via post-synaptic receptor blockade or potentiation and presynaptic vesicular release inhibition. A focused review of the extant scientific literature was conducted, with a discussion of 3 compounds or classes of drugs currently undergoing clinical investigation: ketamine, riluzole, and AMPA receptor potentiators. Recent investigations in mood disordered patients suggest that the NMDA receptor antagonist ketamine might demonstrate rapid antidepressant properties. Riluzole has been shown to reverse glutamate-mediated impairments in neuronal plasticity and to stimulate the synthesis of brain derived neurotrophic factor. Open-label trials in treatment-resistant depression have yielded promising results. Likewise, AMPA receptor potentiators favorably impact neurotrophic factors as well as enhance cognition. CONCLUSIONS: Pharmacological approaches that modulate components of the glutamate system offer novel targets for severe, recurrent mood disorders. Controlled studies are necessary.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The cellular neurobiology of depression
Manji, H. K., Drevets, W. C., & Charney, D. S. (2001) · Nature Medicine · doi:10.1038/87865 · Cited by 1,182
Drevets, W. C. (2001) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00203-8 · Cited by 1,146
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Zafra, F., Hengerer, B., Leibrock, J., Thoenen, H., & Lindholm, D. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb07564.x · Cited by 897
Cotter, D., Mackay, D., Landau, S., Kerwin, R., & Everall, I. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.545 · Cited by 766
Distinct components of spatial learning revealed by prior training and NMDA receptor blockade
Bannerman, D. M., Good, M. A., Butcher, S. P., Ramsay, M., & Morris, R. G. M. (1995) · Nature · doi:10.1038/378182a0 · Cited by 551
Neuroimaging Abnormalities in the Amygdala in Mood Disorders
DREVETS, W. C. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07098.x · Cited by 544
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Corá-Locatelli, G., Leverich, G. S., & Post, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00004 · Cited by 446
Anand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Cited by
Depression gets old fast: do stress and depression accelerate cell aging?
Wolkowitz, O. M., Epel, E. S., Reus, V. I., & Mellon, S. H. (2010) · Depression and Anxiety · doi:10.1002/da.20686 · Cited by 298
Should Depressive Syndromes Be Reclassified as “Metabolic Syndrome Type II”?
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., Woldeyohannes, H. O., Law, C. W. Y., Miranda, A., Fulgosi, D., & Kennedy, S. H. (2007) · Annals of Clinical Psychiatry · doi:10.1080/10401230701653377 · Cited by 277
“Nonetheless, alterations in neuronal plasticity, cellular resilience, and cytoarchitecture, along with associated regional abnormalities in neuronal (and glial) density and morphology are reported (4).”
BackgroundGlutamatergic Modulators: The Future of Treating Mood Disorders?
Zarate, C., Machado-Vieira, R., Henter, I., Ibrahim, L., Diazgranados, N., & Salvadore, G. (2010) · Harvard Review of Psychiatry · doi:10.3109/10673229.2010.511059 · Cited by 228
Mathews, D. C., Henter, I. D., & Zarate, C. A. (2012) · Drugs · doi:10.2165/11633130-000000000-00000 · Cited by 220
Oh, S. J., Ahn, H., Jung, K.-H., Han, S. J., Nam, K. R., Kang, K. J., Park, J.-A., Lee, K. C., Lee, Y. J., & Choi, J. Y. (2020) · Molecular Imaging and Biology · doi:10.1007/s11307-020-01485-w · Cited by 50
Metadata
- Authors
- Mathew, S. J., Keegan, K., & Smith, L.
- Venue
- Revista Brasileira de Psiquiatria
- Publisher
- EDITORA SCIENTIFIC
- Published
- 2005-09
- Volume
- 27
- Issue
- 3
- Pages
- 243-248
- ISSN
- 1516-4446 (ISSN-L)
- OpenAlex
- W2064634505
- Cited by
- 45
- References
- 13
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Glutamate modulators as novel interventions for mood disorders. https://app.cochat.ai/papers/10.1590/s1516-44462005000300016
- The paper
- Mathew, S. J., Keegan, K., & Smith, L. (2005). Glutamate modulators as novel interventions for mood disorders. Revista Brasileira de Psiquiatria. https://doi.org/10.1590/s1516-44462005000300016
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.